Investigational drug · Phase 2
ACR-368
Also called: prexasertib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Endometrial Adenocarcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ACR-368"
First trial start
2022
Aug 29, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ACR-368", any sponsor or status.
Conditions studied
As listed on its trial records.
- Endometrial Adenocarcinoma
Approved drugs for the same conditions: Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ACR-368" as an intervention, largest first.
Acrivon TherapeuticsIndustry
NCT05548296 · 350 participants (planned) · Start Aug 29, 2022 · Primary completion May 30, 2027
Drug: ACR-368; Gemcitabine · For: Endometrial Adenocarcinoma
Sites: Mobile, Alabama; Anchorage, Alaska; Phoenix, Arizona · 90 sites in all
H. Lee Moffitt Cancer Center and Research InstituteAcademic, hospital or other
NCT06597565 · 43 participants (planned) · Start Sep 25, 2024 · Primary completion Aug 23, 2028
Drug: Gemcitabine; ACR-368 · For: Head and Neck Squamous Cell Carcinoma
Sites: Tampa, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of potent, selective, and orally bioavailable monocyclic pyridine-based PKMYT1 inhibitors that synergize with CHK1 inhibition in replication-stressed cancer cells.
Sun Y, Chu H, Wei Y, et al. · Bioorg Med Chem Lett 2027
- CHK1/2 as a potential therapeutic target in Neurofibromatosis type 2 schwannomas.
Benton D, Khusnutdinov R, Buts M, et al. · Cancer Lett 2026
- Dual CHK1 and WNT Inhibition as a Synergistic Therapy for Gastrointestinal Neuroendocrine Carcinoma.
Kimura H, Sato Y, Yachida S · Cancer Res Commun 2026
- Nuclear Cathepsin L Remodels the Replication Machinery to Create a Therapeutic Vulnerability in Ovarian Cancer.
Thirusangu P, Jin L, Rao S, et al. · bioRxiv 2026
- Integrative Bioinformatics Identification of Baicalein as a Phytochemical Inhibitor of CHEK1 in Serous Ovarian Cancer: A Multi-Stage In Silico Drug Discovery Approach.
Jayagopal P, Prabhakar S, Ponneri Adithavarman A, et al. · Pharmaceuticals (Basel) 2026
- Chk1 inhibition emerges as the most effective partner for PARP inhibition in BRCA-proficient pancreatic cancer.
Morimoto Y, Musha Y, Takeuchi O, et al. · Discov Oncol 2026
Also in development for Endometrial Adenocarcinoma
- ETX-929Phase 21 trial
Ensem Therapeutics · Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.